Thrombospondins and tumor angiogenesis

Trends in Molecular Medicine

Volumn 7, Issue 9, 2001, Pages 401-407

  De Fraipont, Florence ^a   Nicholson, Ainsley C ^b   Feige, Jean Jacques ^a   Van Meir, Erwin G ^b  

^a CEA GRENOBLE   (France)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; THROMBOSPONDIN;

ANTINEOPLASTIC ACTIVITY; CANCER GRADING; CANCER SURVIVAL; DRUG RECEPTOR BINDING; HYPOXIA; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; SOLID TUMOR; TUMOR VASCULARIZATION;

EID: 0034853482     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(01)02102-5     Document Type: Review

References (75)

1. Thrombospondins
2. Thrombospondins
3. The functions of thrombospondin-1 and -2
4. Differential expression of thrombospondin 1, 2, and 3 during murine development
5. Colocalization of thrombospondin and syndecan during murine development
6. The distribution of the matricellular protein thrombospondin 2 in tissues of embryonic and adult mice
7. Bovine thrombospondin-2: Complete complementary deoxyribonucleic acid sequence and immunolocalization in the external zones of the adrenal cortex
8. The cell biology of thrombospondin-1
9. Cell contact-dependent activation of α3β1 integrin modulates endothelial cell responses to thrombospondin-1
10. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1
11. Metabolism of thrombospondin 2. Binding and degradation by 3T3 cells and glycosaminoglycan-variant Chinese hamster ovary cells
12. The thrombospondin type 1 repeat (TSR) superfamily: Diverse proteins with related roles in neuronal development
13. The evolution of cell adhesion
14. The functions of thrombospondin and its involvement in physiology and pathophysiology
15. Thrombospondin as a regulator of angiogenesis
16. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene
17. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin
18. Inhibition of angiogenesis by thrombospondin-2
19. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity
20. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: A potential angiogenesis regulatory factor
21. Activation of latent TGF-β by thrombospondin-1: Mechanisms and physiology
22. Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway
23. The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells
24. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia
25. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis
26. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
27. Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells
28. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor
29. Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells
30. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
31. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity
32. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells
33. Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression
34. Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma
35. Thrombospondins I and II messenger RNA expression in lung carcinoma: Relationship with p53 alterations, angiogenic growth factors, and vascular density
36. The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun
37. SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts
38. Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells
39. Transformation by v-src causes transient induction followed by repression of mouse thrombospondin-1
40. Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene
41. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines
42. Tumoral vascularity as a prognostic factor in cancer
43. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast
44. Stromal thrombospondin-1 expression is correlated with progression of esophageal squamous cell carcinomas
45. Stromal expression of thrombospondin-1 is correlated with growth and metastasis of human gallbladder carcinoma
46. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features
47. Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: Correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia
48. Thrombospondin in malignant and non-malignant breast tissue
49. Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma
50. Expression of angiostatic factors in colorectal cancer
51. Expression of the angiogenesis markers vascular endothelial growth factor, thrombospondin-1 and platelet-derived endothelial growth factor in human sporadic adrenocortical tumors. Correlation with genotypic alterations
52. Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer
53. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1
54. Thrombospondin-2 (TSP2) expression is inversely correlated with vascularity in glioma
55. Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer
56. Thrombospondins selectively activate one of the two latent forms of transforming growth factor-β present in adrenocortical cell-conditioned medium
57. Activation of rat alveolar macrophage-derived latent transforming growth factor β-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36
58. Thrombospondin-1 is a major activator of TGF-β1 in vivo
59. Activation of platelet transforming growth factor-β 1 in the absence of thrombospondin-1
60. Blood vessel formation: What is its molecular basis?
61. The plasminogen activation system in tumor growth, invasion, and metastasis
62. Thrombospondin levels in patients with malignancy
63. Plasma thrombospondin levels in patients with gynecologic malignancies
64. Plasma thrombospondin levels in patients with colorectal carcinoma
65. Tumor vasculature targeted therapies: Getting the players organized
66. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis
67. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1
68. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization
69. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas
70. Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis
71. Treatment of experimental brain tumors with thrombospondin-1 derived peptides: An in vivo imaging study
72. Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma
73. Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor
74. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma
75. Matrix-bound thrombospondin promotes angiogenesis in vitro